Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial

ROCKET AF Investigators, Daniel E Singer, Anne S Hellkamp, Jonathan P Piccini, Kenneth W Mahaffey, Yuliya Lokhnygina, Guohua Pan, Jonathan L Halperin, Richard C Becker, Günter Breithardt, Graeme J Hankey, Werner Hacke, Christopher C Nessel, Manesh R Patel, Robert M Califf, Keith A A Fox

Research output: Contribution to journalArticlepeer-review

Abstract

Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial.
Original languageEnglish
Pages (from-to)e000067
JournalJournal of the American Heart Association Cardiovascular and Cerebrovascular Disease
Volume2
Issue number1
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Dive into the research topics of 'Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial'. Together they form a unique fingerprint.

Cite this